Business
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
SAN DIEGO , Feb. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential cla...
About this update from Linear Minerals Corp.
[{"type":"text","content":"Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)\nSAN DIEGO , Feb. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Jasper Therapeutics, Inc. (NASDAQ: JSPR), KBR, Inc. (NYSE: KBR), LifeMD, Inc. (NASDAQ: LFMD), and Lineage, Inc. (NASDAQ: LINE) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who have held shares continuously since prior to the dates listed below may have standing to seek corporate governance reforms focused on executive oversight, the return of funds to the Company, and a court-approved incentive award, at no cost to them. Jasper Therapeutics, Inc. (NASDAQ: JSPR) If you have held Jasper Therapeutics shares continuously since prior to November 30, 2023, you may have standing to seek corporate governance reforms focused on executive oversight at Jasper Therapeutics. To learn more, visit:https://www.johnsonfistel.com/investigations/jasper-therapeutics-inc/or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. Complaint AllegationsA previously filed securities class action complaint alleges that throughout the class period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked adequate controls and procedures to ensure that third-party manufacturers were producing products in full compliance with cGMP requirements and otherwise suitable for clinical trial use; (2) these deficiencies increased the risk that clinical study results would be confounded, adversely impacting the regulatory and commercial prospects of the Company’s product candidates, including briquilimab; (3) these issues increased the likelihood that Jasper would be forced to implement disruptive cost-reduction measures; (4) as a result, the Company’s business and financial prospects were overstated; and (5) Defendants’ positive statements regarding the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. KBR, Inc. (NYSE: KBR) If you have held KBR shares continuously since prior to May 6, 2025, you may have standing to seek corporate governanc...